A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms

NCT02857998 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Mature B-cell Neoplasms

Interventions

DRUG: HMPL-523

Sponsor

Hutchison Medipharma Limited